We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Astellas Pharma Inc | TG:YPH | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| 0.21 | 2.34% | 9.20 | 9.028 | 9.22 |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 9.312 | 9.072 | 9.312 | 906 | 16:24:58 |
| Date | Time | Source | Headline |
|---|---|---|---|
| 22/4/2024 | 20:41 | ALNC |  Takeda, Astellas and Sumitomo to create new drug discovery company |
| 11/3/2024 | 15:37 | ALNC | IN BRIEF: Astellas receives FDA exclusivity approval for Cresemba |
| 11/3/2024 | 13:16 | ALNC | *Astellas: FDA grants drug exclusivity to Cresemba aspergillosis,.. |
| 20/2/2024 | 21:15 | ALNC | Merck and Astellas drugs get priority review in US and Japan |
| 29/1/2024 | 08:26 | ALNC | Astellas and Pfizer's Padcev validated by EMA to treat bladder cancer |
| 18/12/2023 | 11:04 | ALNC | Astellas, Merck, Pfizer celebrate US approval for Keytruda plus Padcev |
| 08/12/2023 | 20:07 | ALNC | IN BRIEF: Astellas Pharma announces US FDA green light for Cresemba |
1 Year Astellas Pharma Chart |
Intraday Astellas Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
